Rosuvastatin News and Research

RSS

Simcere Pharmaceutical Group signs agreement to acquire manufacturing license from Tianjin Tianda Pharmaceutical

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement to acquire the manufacturing license in China of Rosuvastatin from Tianjin Tianda Pharmaceutical Co., Ltd. ("Tianda").

9 Nov 2009

AstraZeneca's CRESTOR approved for treating pediatric patients with HeFH

AstraZeneca today announced the U.S. Food and Drug Administration (FDA) approved CRESTOR® (rosuvastatin calcium) for use in pediatric patients ages 10-17 with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol. HeFH, a genetic disease, is characterized by high LDL cholesterol (the "bad" cholesterol) and increased risk of early cardiovascular disease.

19 Oct 2009

Drug design: palladium catalyst used to attach fluorine atom to aromatic compounds

A team of MIT chemists has devised a new way to add fluorine to a variety of compounds used in many drugs and agricultural chemicals, an advance that could offer more flexibility and potential cost-savings in designing new drugs.

13 Aug 2009

NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management

Data from a new study showed that Abbott's TRILIPIX (fenofibric acid) delayed-release capsules in combination with rosuvastatin calcium met all of the study's primary endpoints.

29 Mar 2009

CRESTOR found to reduced CV risk in patients achieving low LDL-C and hsCRP targets in new Jupiter analysis

Results from a new sub-analysis of the JUPITER study show that patients who attained a dual treatment target of LDL-C <70mg/dL and high-sensitivity C-reactive protein (hsCRP) <2mg/L with CRESTOR (rosuvastatin) 20mg achieved a greater reduction in cardiovascular events compared to placebo than those who did not (65% vs 36%, p=0.033) among men and women with low to normal cholesterol levels and elevated hsCRP.

29 Mar 2009

CRESTOR (rosuvastatin) shown to significantly reduce risk of venous thromboembolism

A new analysis from the JUPITER study shows that CRESTOR (rosuvastatin) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p=0.007) compared to placebo among men and women with low to normal cholesterol levels and elevated high-sensitivity C-reactive protein (hsCRP).

29 Mar 2009

Statins can stimulate cardiac muscle cell regeneration, improve heart function

Statins, used widely to treat elevated cholesterol, have been shown to prevent progression of coronary narrowing and to have other beneficial effects on the heart, such as reducing inflammation, that are independent of cholesterol.

23 Feb 2009

Numerical analysis estimates numbers of older US adults who may benefit from statin therapy

Researchers estimate more than 11 million older Americans may be newly eligible for statin therapy if findings from a recently published large clinical trial are adopted into clinical practice guidelines, according to a new analysis of the trial data.

13 Jan 2009

Rosuvastatin trial shows dramatic reduction in hidden heart disease

A Harvard-led study shows that the risk of heart attack and stroke among subjects with "silent heart disease" - and normal cholesterol levels - can be dramatically reduced by the use of an already widely prescribed class of drugs.

13 Nov 2008

Simple blood test for high-sensitivity C-reactive protein is a useful marker for cardiovascular disease

This year, about 450,000 Americans will die of coronary heart disease – the leading cause of death for both men and women.

11 Nov 2008

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.

10 Nov 2008

Metabolic genes tied to inflammatory predictor of heart disease and stroke risk

Two new studies provide evidence that differences in people's blood levels of C reactive protein (CRP) stem in part from natural variation in known metabolic genes. The researchers report their findings in the May American Journal of Human Genetics, a publication of Cell Press.

24 Apr 2008

Genomas awarded $1.2 million to develop DNA-guided system for management of statin therapy

Genomas, a biomedical company advancing DNA-guided medicine and personalized healthcare, has announced the award of a Fast-Track Phase I-II Small Business Innovation Research (SBIR) Grant totaling $1.2 million.

20 Mar 2008

Abbott and AstraZeneca confirm Phase III clinical trials of Fenofibrate ABT-335 and Crestor as fixed-dose combination

Abbott and AstraZeneca confirmed they will advance the development of Abbott's next-generation fenofibrate ABT-335 and AstraZeneca's CRESTOR (rosuvastatin calcium) in a fixed-dose combination treatment into Phase III clinical trials.

3 Sep 2007

Rosuvastatin well tolerated by a broad range of patients with dyslipidemia

The safety and tolerability of rosuvastatin were assessed using data from 16,876 patients who received rosuvastatin 5-40 mg in a multinational phase II/III/IIIb/IV program, representing 25,670 patient-years of continuous exposure to rosuvastatin. An integrated database, consisting of 33 trials whose databases were locked up to and including September 16, 2005, was used to examine adverse events and laboratory data.

9 May 2007

Statins slow the progression of aortic valve stenosis

The trial provides the first prospective clinical evidence that aortic valves have an active biology that can be targeted with medical therapy and contradicts research published in 2005 in the New England Journal of Medicine, which concluded statins did not halt the progression of aortic stenosis.

30 Jan 2007

Intensive statin therapy shows promise for inducing regression of coronary atherosclerosis

Patients treated with very intensive statin therapy lowered LDL-C levels on average by about 50 percent, increased HDL-C levels by 15 percent, and showed regression of coronary atherosclerosis

15 Mar 2006

Intensive cholesterol lowering with a statins can partially reverse the buildup of plaque in the coronary arteries

A study presented at the American College of Cardiology's 55th Annual Scientific Session demonstrates, for the first time, that very intensive cholesterol lowering with a statin drug can regress (partially reverse) the buildup of plaque in the coronary arteries.

14 Mar 2006

Most serious side effects in statins may be higher in one of the newest drugs, rosuvastatin (Crestor)

A post-market analysis of cholesterol-lowering drugs called statins indicates that some of the most serious side effects may be higher in one of the newest drugs, rosuvastatin (Crestor). The drug is the strongest statin available because it has the greatest effect per milligram on low-density lipoprotein ("bad" cholesterol).

26 May 2005

New statin study shows arrested progression of atherosclerosis

The first study to use cutting edge magnetic resonance imaging to examine the effect of a statin - rosuvastatin (Crestor) - on the fatty plaques in arteries, was presented yesterday at the 75th European Atherosclerosis Society Congress. ORION revealed that rosuvastatin has a beneficial effect on the size and composition of fatty plaques in arteries (specifically the carotid artery in the neck). Fatty plaques that are vulnerable to sudden rupture can cause heart attacks and strokes without warning.

25 Apr 2005

Rosuvastatin News and Research

Simcere Pharmaceutical Group signs agreement to acquire manufacturing license from Tianjin Tianda Pharmaceutical

AstraZeneca's CRESTOR approved for treating pediatric patients with HeFH

Drug design: palladium catalyst used to attach fluorine atom to aromatic compounds

NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management

CRESTOR found to reduced CV risk in patients achieving low LDL-C and hsCRP targets in new Jupiter analysis

CRESTOR (rosuvastatin) shown to significantly reduce risk of venous thromboembolism

Statins can stimulate cardiac muscle cell regeneration, improve heart function

Numerical analysis estimates numbers of older US adults who may benefit from statin therapy

Rosuvastatin trial shows dramatic reduction in hidden heart disease

Simple blood test for high-sensitivity C-reactive protein is a useful marker for cardiovascular disease

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

Metabolic genes tied to inflammatory predictor of heart disease and stroke risk

Genomas awarded $1.2 million to develop DNA-guided system for management of statin therapy

Abbott and AstraZeneca confirm Phase III clinical trials of Fenofibrate ABT-335 and Crestor as fixed-dose combination

Rosuvastatin well tolerated by a broad range of patients with dyslipidemia

Statins slow the progression of aortic valve stenosis

Intensive statin therapy shows promise for inducing regression of coronary atherosclerosis

Intensive cholesterol lowering with a statins can partially reverse the buildup of plaque in the coronary arteries

Most serious side effects in statins may be higher in one of the newest drugs, rosuvastatin (Crestor)

New statin study shows arrested progression of atherosclerosis

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News